Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tucatinib

AstraZeneca AZ

AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

Filing due later this year

- PMLiVE

NICE gives Lilly’s Verzenios chance to compete with rivals

Breast cancer drug also being appraised in novel combination

- PMLiVE

Roche gains speedy review for Tecentriq in first-line breast cancer

Set to become the first immunotherapy for triple negative breast cancer

Eli Lilly HQ

Lilly gets EMA nod for Verzenio in breast cancer

And puts pressure on Pfizer’s market leading Ibrance and Novartis’ Kisqali

- PMLiVE

Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

Contender could offer potency without dose-limiting toxicities

- PMLiVE

Novartis considers filings for PI3K drug in breast cancer

Those treated with alpelisib had longer PFS than those on fulvestrant alone

- PMLiVE

Daily Brief: Europe changes mind on Puma drug, Pfizer’s Healthcare Hub, AbbVie and Calico add $1bn to anti-ageing quest

The latest from pharma, biotech and healthcare

- PMLiVE

ACT immunotherapy cures terminal breast cancer patient

The new approach focuses on mutations rather than cancer type

- PMLiVE

Seattle Genetics claims key US approval for Adcetris

Becomes the first new treatment for advanced Hl in more than 40 years

- PMLiVE

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

Will launch Herzuma in seven European countries including the UK and Germany

- PMLiVE

FDA approves another home genetic testing service

23andMe’s kit will check for an increased risk of certain cancers developing

- PMLiVE

MSD launches EU’s first biosimilar Herceptin in UK

Ontruzant is set to be strong competition for Roche’s blockbuster

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links